FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068656369> ?p ?o ?g. }

• W2068656369 endingPage "13" @default.
• W2068656369 startingPage "1744" @default.
• W2068656369 abstract "Background:Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system lesions. The etiology of neuropathic pain consists of several overlapping pathways converging into an exaggerated pain state with symptoms such as allodynia and hyperalgesia. One of these pathways involves activation of spinal cord microglia and astrocytes, which drive and maintain the inflammatory response following the lesion. These cells are a potential target for drugs for neuropathic pain relief. In this current study, we investigated the dose-effect relationship of the tissue protective peptide ARA 290, derived from the tertiary structure of erythropoietin, on allodynia and concurrent spinal cord microglia and astrocytes. Results:Following a spared nerve injury in rats, vehicle or ARA290 (administered in either one of 4 doses: 3, 10, 30 and 60 μg/kg) was administered on days 1, 3, 6, 8 and 10. ARA290 exerted a dose-response effect by significantly reducing mechanical allodynia up to 20 weeks when compared to vehicle. The reduction of cold allodynia was significant up to 20 weeks for the doses 3, 10, 30 and 60 μg/kg when compared to vehicle. The effect 10 and 30 μg/kg ARA290 and vehicle on the microglia response (iba-1-immunoreactivity, iba-1-IR) and astrocyte reaction (GFAP-immunoreactivity, GFAP-IR) was investigated in animals surviving 2 (group 1) or 20 (group 2) weeks following lesion or sham surgery. In group 1, significant microglia reactivity was observed in the L5 segment of the spinal cord of animals treated with vehicle when compared to sham operated, while animals treated with 10 or 30 μg/kg did not show a increase. In group 2, a more widespread and increased microglia reactivity was observed for animals treated with 0 and 10 μg/kg when compared to sham operated animals, indicated by involvement of more spinal cord segments and higher iba-1-IR. Animals treated with 30 μg/kg did not show increased microglia reactivity. No difference in astrocyte reaction was observed. Conclusions:The erythropoietin-analogue ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response, suggestive of a mechanistic link between ARA290-induced suppression of central inflammation and relief of neuropathic pain symptoms." @default.
• W2068656369 created "2016-06-24" @default.
• W2068656369 creator A5025863770 @default.
• W2068656369 creator A5029709460 @default.
• W2068656369 creator A5041229784 @default.
• W2068656369 creator A5077603374 @default.
• W2068656369 creator A5078916012 @default.
• W2068656369 creator A5079099806 @default.
• W2068656369 creator A5085079099 @default.
• W2068656369 creator A5089013775 @default.
• W2068656369 date "2014-01-01" @default.
• W2068656369 modified "2023-09-27" @default.
• W2068656369 title "ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response" @default.
• W2068656369 cites W1550940982 @default.
• W2068656369 cites W1582090951 @default.
• W2068656369 cites W1814675358 @default.
• W2068656369 cites W1841237986 @default.
• W2068656369 cites W1855047800 @default.
• W2068656369 cites W1967334494 @default.
• W2068656369 cites W1969771733 @default.
• W2068656369 cites W1980155039 @default.
• W2068656369 cites W1982534244 @default.
• W2068656369 cites W1988209540 @default.
• W2068656369 cites W2006161356 @default.
• W2068656369 cites W2009140810 @default.
• W2068656369 cites W2009761130 @default.
• W2068656369 cites W2014313724 @default.
• W2068656369 cites W2015676327 @default.
• W2068656369 cites W2016052090 @default.
• W2068656369 cites W2022421837 @default.
• W2068656369 cites W2037132368 @default.
• W2068656369 cites W2044639383 @default.
• W2068656369 cites W2051300373 @default.
• W2068656369 cites W2057855349 @default.
• W2068656369 cites W2070312747 @default.
• W2068656369 cites W2077885131 @default.
• W2068656369 cites W2083497063 @default.
• W2068656369 cites W2085384344 @default.
• W2068656369 cites W2086869271 @default.
• W2068656369 cites W2087454739 @default.
• W2068656369 cites W2092057596 @default.
• W2068656369 cites W2092408017 @default.
• W2068656369 cites W2092413554 @default.
• W2068656369 cites W2093705470 @default.
• W2068656369 cites W2095387649 @default.
• W2068656369 cites W2100726312 @default.
• W2068656369 cites W2102795473 @default.
• W2068656369 cites W2106137006 @default.
• W2068656369 cites W2110788486 @default.
• W2068656369 cites W2113154361 @default.
• W2068656369 cites W2115257592 @default.
• W2068656369 cites W2121141076 @default.
• W2068656369 cites W2127070923 @default.
• W2068656369 cites W2135826900 @default.
• W2068656369 cites W2140441724 @default.
• W2068656369 cites W2149599746 @default.
• W2068656369 cites W2157425708 @default.
• W2068656369 cites W2161854192 @default.
• W2068656369 cites W2164531304 @default.
• W2068656369 cites W2166803676 @default.
• W2068656369 cites W2170019750 @default.
• W2068656369 cites W4238492973 @default.
• W2068656369 cites W91891120 @default.
• W2068656369 doi "https://doi.org/10.1186/1744-8069-10-13" @default.
• W2068656369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3928087" @default.
• W2068656369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24529189" @default.
• W2068656369 hasPublicationYear "2014" @default.
• W2068656369 type Work @default.
• W2068656369 sameAs 2068656369 @default.
• W2068656369 citedByCount "28" @default.
• W2068656369 countsByYear W20686563692014 @default.
• W2068656369 countsByYear W20686563692015 @default.
• W2068656369 countsByYear W20686563692016 @default.
• W2068656369 countsByYear W20686563692017 @default.
• W2068656369 countsByYear W20686563692018 @default.
• W2068656369 countsByYear W20686563692019 @default.
• W2068656369 countsByYear W20686563692020 @default.
• W2068656369 countsByYear W20686563692021 @default.
• W2068656369 countsByYear W20686563692022 @default.
• W2068656369 countsByYear W20686563692023 @default.
• W2068656369 crossrefType "journal-article" @default.
• W2068656369 hasAuthorship W2068656369A5025863770 @default.
• W2068656369 hasAuthorship W2068656369A5029709460 @default.
• W2068656369 hasAuthorship W2068656369A5041229784 @default.
• W2068656369 hasAuthorship W2068656369A5077603374 @default.
• W2068656369 hasAuthorship W2068656369A5078916012 @default.
• W2068656369 hasAuthorship W2068656369A5079099806 @default.
• W2068656369 hasAuthorship W2068656369A5085079099 @default.
• W2068656369 hasAuthorship W2068656369A5089013775 @default.
• W2068656369 hasBestOaLocation W20686563691 @default.
• W2068656369 hasConcept C118552586 @default.
• W2068656369 hasConcept C126322002 @default.
• W2068656369 hasConcept C142724271 @default.
• W2068656369 hasConcept C15490471 @default.
• W2068656369 hasConcept C170493617 @default.
• W2068656369 hasConcept C185592680 @default.
• W2068656369 hasConcept C2776914184 @default.
• W2068656369 hasConcept C2777107010 @default.

• next